Keyword      Search in       

Contact
Imprint
Site Map

RSS Feed News. Your shopping cart.

Google gadget.

GMP News
01/09/2010
 

New Toxicological Data on Isopropylbenzene Trigger its Categorisation as Class 2 Solvent

  
The ICH Guideline Q3C defining the limits for residual solvents as impurities in active pharmaceutical ingredients (APIs) and finished medicinal products as well as the methods for establishing their exposure limits has already been revised four times. The revisions concern among others provisions for calculating the PDEs (PDE = permissible daily exposure, denoting the maximum amount of a solvent that may be taken in with a medicinal product) for the solvents N-Methylpyrrolidone and Tetrahydrofuran. Now the guideline is about to be revised once more, the reason being that new toxicological data have been collected on the solvent Isopropylbenzene (called "Cumene" in the guideline). Hitherto, this substance has been categorised as Class 3, i.e. as a solvent with low toxicity. In general, these solvents have PDE values of 50 mg per day or more. Recent toxicity studies conducted in rats and mice clearly showed a heightened carcinogenic potential so that it has become necessary to assign Isopropylbenzene to the higher Class 2 and to calculate the PDE accordingly.
On 26 March 2010, the ICH Draft Consensus Guideline "Impurities: Guideline for Residual Solvents - PDE for Cumene" was published (Step 2 in the ICH process) and has since been available for commenting by the public. This guideline now requires the calculation of the PDE for Isopropylbenzene according to the rules for Class 2 solvents. After two further steps in the ICH process, this guideline will be integrated into the core document, which will then bear the name ICH Q3C(R5).

This new regulation might require manufacturers of APIs and medicinal products using Isopropylbenzene to make a considerable effort in changing their registration dossier (e. g. as a consequence of changes to the manufacturing process, the analytical methods etc.).

Here you can find the new ICH Draft Consensus Guideline and the Guideline Q3C(R4).

Author:
Dr Gerhard Becker
On behalf of the European Compliance Academy (ECA)

Related GMP News
08/02/2012New Questions and Answers about the Centralised Procedure - EMA publishes an Updated Q&A Document
01/02/2012FDA: QbD becomes mandatory for Generics
09/11/2011New QP Declaration for managing Expiry Dates of IMPs
09/11/2011MHRA announces Good Clinical Practice (GCP) Discussion Forum
26/10/2011CHMP adopts Guideline on Quality Aspects on the Isolation of Candidate Influenza Vaccine Viruses